Analysts Set Merus (NASDAQ:MRUS) Price Target at $85.31

Shares of Merus (NASDAQ:MRUS - Get Free Report) have been assigned a consensus recommendation of "Buy" from the sixteen research firms that are presently covering the company, Marketbeat.com reports. Fourteen research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $85.31.

A number of analysts have recently issued reports on the company. Citigroup lifted their target price on Merus from $89.00 to $97.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Wells Fargo & Company assumed coverage on Merus in a report on Friday, February 7th. They set an "overweight" rating and a $91.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $85.00 target price on shares of Merus in a research note on Monday, March 3rd. Needham & Company LLC cut their price target on shares of Merus from $85.00 to $83.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Finally, William Blair reiterated an "outperform" rating on shares of Merus in a research note on Friday, February 28th.

Institutional Trading of Merus

A number of institutional investors and hedge funds have recently made changes to their positions in MRUS. State of Wyoming bought a new position in Merus during the 4th quarter worth $48,000. Wells Fargo & Company MN grew its position in shares of Merus by 27.3% during the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 300 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Merus in the 4th quarter worth about $60,000. Avior Wealth Management LLC bought a new stake in Merus in the 4th quarter valued at about $76,000. Finally, Lazard Asset Management LLC acquired a new position in Merus during the 4th quarter valued at about $84,000. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Merus Stock Performance

Shares of NASDAQ:MRUS traded down $1.52 during mid-day trading on Thursday, hitting $47.64. 710,060 shares of the company traded hands, compared to its average volume of 650,780. The firm's 50 day simple moving average is $42.71 and its 200 day simple moving average is $46.42. The firm has a market cap of $3.29 billion, a P/E ratio of -12.06 and a beta of 1.15. Merus has a 52-week low of $37.77 and a 52-week high of $61.61.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The business had revenue of $9.14 million during the quarter, compared to analyst estimates of $10.57 million. Equities research analysts expect that Merus will post -3.85 EPS for the current fiscal year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.